BG
RCKT icon

Bellevue Group’s Rocket Pharmaceuticals RCKT Stock Holding History

Bellevue Group’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-9,300
Closed -$172K – 172
2024
Q3 		$172K Sell
9,300
-10,400
-53% -$213K ﹤0.01% 151
2024
Q2 		$424K Hold
19,700
– – 0.01% 132
2024
Q1 		$531K Sell
19,700
-1,300
-6% -$36.9K 0.01% 129
2023
Q4 		$629K Buy
+21,000
New +$463K 0.01% 130
2023
Q3 		– Sell
-55,600
Closed -$1.1M – 162
2023
Q2 		$1.1M Buy
55,600
+19,000
+52% +$384K 0.02% 128
2023
Q1 		$627K Hold
36,600
– – 0.01% 138
2022
Q4 		$716K Buy
+36,600
New +$674K 0.01% 145

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Bellevue Group's RCKT Position: Q4 2024 in Review

Bellevue Group sold out of Rocket Pharmaceuticals (RCKT) in Q4 2024, closing a stake of 9,300 shares — an estimated $172K sold.

Bellevue Group first reported a position in RCKT in Q4 2022 and held it in 7 quarters. The position peaked at $1.1M in Q2 2023. 225 funds tracked by Wall St. Rank hold RCKT as of Q4 2024.

  • Bellevue Group reported no remaining Rocket Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Bellevue Group sold 9,300 Rocket Pharmaceuticals shares in Q4 2024, an estimated $172K.
  • Bellevue Group first reported a position in Rocket Pharmaceuticals in Q4 2022 and held it in 7 quarters.
  • Bellevue Group's Rocket Pharmaceuticals position peaked at $1.1M in Q2 2023.
  • 225 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q4 2024.

Based on Bellevue Group's 13F filing for Q4 2024, filed 14 Feb 2025.